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Abstract
Background: Visceral adipose tissue (VAT) was shown to be increased in patients with chronic obstructive
pulmonary disease (COPD) compared to control subjects with comparable body mass index (BMI). Our aim was to
determine the relation of VAT by dual-energy x-ray absorptiometry (DEXA) in patients with COPD by disease
severity, BMI, other indices of body composition and static lung volumes.
Methods: 294 COPD patients admitted for rehabilitation were studied. Lung function, static lung volumes and
body composition (i.e. BMI, waist circumference, fat-free mass, fat mass and fat distribution between android and
gynoid fat mass) were assessed before entering pulmonary rehabilitation. VAT was estimated within the android
region by using DEXA. Patients were stratified for gender, BMI (cut-off of 25 kg/m2) and GOLD stage. To assess the
impact of VAT on lung volumes, patients were also stratified for VAT less and above 50th percentile.
Results: Both male and female patients with more severe airflow limitation had significantly lower VAT values, but
these differences disappeared after stratification for BMI. VAT was significantly and strongly correlated with other
body composition parameters (all p < 0.001). Patients with moderate to severe airflow limitation and lower VAT had
increased static lung hyperinflation and lower diffusing capacity for carbon monoxide. Nevertheless, multivariate
stepwise regression models including for BMI, age, gender and forced expiratory volume in 1 s (FEV1) as
confounders did not confirm an independent role for VAT on static lung hyperinflation and diffusion capacity.
Conclusion: After stratification for BMI, VAT is comparable in moderate to very severe COPD patients. Furthermore,
BMI and demographics, but not VAT, were independent predictors of static lung hyperinflation and diffusing
capacity in COPD.
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Background
Although defined by the presence of persistent airflow
limitation [1], alterations in body weight and body compos-
ition contribute to disease severity in patients with chronic
obstructive pulmonary disease (COPD). Indeed, low body
mass index (BMI) (<21 kg/m2) is related to poor exercise
tolerance [2], low fat-free mass (FFM) [3] and co-morbid
osteoporosis [4]. Furthermore, it is incorporated in the
prognostic assessment of COPD [5]. Otherwise, high BMI
(≥30 kg/m2) is related to increased dyspnea [6], reduced
weight-bearing exercise performance [7] and systemic
inflammation in COPD. [3] At the same time, reductions
in lung volumes have been consistently reported in obese
COPD patients [8].
In addition to the discriminating role of BMI in the
clinical phenotyping of COPD patients, alterations in
body composition, i.e. the distribution between FFM and
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fat mass (FM), are common and have additional impact
on the burden of disease. In more detail, visceral adipose
tissue (VAT) is receiving increasing attention in COPD,
since it was shown that elderly subjects with obstructive
lung disease have increased visceral adipose area in com-
parison with control subjects with comparable BMI [9].
Also, there is increasing evidence for a role of VAT in the
pathophysiology of systemic inflammation [10] and car-
diovascular morbidity in COPD [10, 11]. Typically, VAT is
assessed by computer tomography (CT) or magnetic
resonance imaging (MRI), but these measurements are
expensive, time-consuming and not widely available.
Alternatively, dual-energy x-ray absorptiometry (DEXA) is
a commonly used device with lower radiation dose, alter-
native to estimate body composition in COPD and was
recently introduced as a validated method to quantify
VAT [12, 13]. However, no clinical studies investigating
VAT with DEXA are available in COPD patients. Thus, as-
sociations between VAT assessed by this method and
other traditional markers of body composition in COPD
are currently unknown. Also, the impact of VAT per se on
lung volumes has not been studied in COPD.
Therefore, the aims of the present study were: 1) to
quantify the amount of VAT measured by DEXA in
patients with COPD in relation to disease severity and
BMI; 2) to explore the relationships between VAT and
other indices of body composition and 3) to study the
impact of VAT on static lung volumes. In the present
study, we hypothesized that VAT does significantly and
negatively influence static lung volumes and hyperinfla-
tion in patients with COPD.
Methods
Patient selection
Data were abstracted from the Integrated Knowledge
System based on BioXM™ (Biomax Informatics AG,
Munich, Germany) of 294 patients with a primary diagnosis
of COPD [post-bronchodilator forced expiratory volume in
1 s (FEV1) /forced vital capacity (FVC) ratio of ⩽0.70 and
post-bronchodilator FEV1 < 80 % predicted] who were eval-
uated during the initial assessment of a comprehensive pul-
monary rehabilitation (PR) program at CIRO Horn (The
Netherlands) between August 2014 and May 2015 [14]. Ex-
clusion criteria were: a history of asthma, α1-antitrypsin de-
ficiency, lung cancer, any previous lung surgery, instable
inflammatory or endocrine diseases, acute myocardial in-
farction within the last 6 months, any known bone disease
other than osteoporosis, treated malignant disease within
the last 5 years and an exacerbation of COPD within the last
4 weeks. Ethical approval was not indicated because all of
the tests were done as part of the routine initial assessment
[14], and analyzed retrospectively. The Board of Directors of
CIRO approved the use of de-identified patients’ records.
Lung function measurement
As part of the routine 3-day initial assessment of integrated
health status, all patients performed post-bronchodilator
spirometry (Masterlab®; Jaeger, Würzburg, Germany). FEV1
and FVC were assessed in accordance with the latest
GOLD guidelines [1]. Inspiratory vital capacity (IVC) was
assessed too. Plethysmographic lung volumes, such as Total
Lung Capacity (TLC), Intra Thoracic Gas Volume (ITGV),
Expiratory Reserve Volume (ERV) and Residual Volume
(RV) were assessed. Inspiratory Capacity(IC)/TLC ratio
[15] was calculated by dividing TLC − ITGV for TLC, and
was used as a marker for hyperinflation (defined as an ab-
normal increase in the volume of air remaining in the lungs
at the end of spontaneous expiration [16]). Diffusing cap-
acity of the lung for carbon monoxide (DLCO) was mea-
sured using the single-breath method. All obtained values
are expressed as percentages of the predicted value, by
comparison with age and sex-specific reference values [17].
Body composition
Body height was measured to the nearest 0.5 cm with a
wall-mounted stadiometer. Body weight was assessed to
the nearest 0.1 kg using a weighing scale, and BMI was
calculated as weight/height2. A total body scan was per-
formed by DEXA using a Lunar Prodigy® system (GE
Healthcare - enCORE v14, Madison, WI, USA). Subjects
lay supine on the DEXA table with arms adequately sep-
arated from the trunk and were instructed to remain still
throughout the scanning procedure. After analysis of the
whole body scan, a quadrilateral box was manually
drawn around the L1–L4 region of interest (abdomen)
bounded inferiorly by the horizontal line identifying L4/
L5 vertebral space and superiorly by the horizontal line
identifying the T12/L1 vertebral space. Scans were dis-
played with an adjustment of the gray scale, so that all
of the soft tissue in the designated area was included.
From the total body scan, body composition was
assessed: bone mineral content (BMC), lean mass (LM),
FFM (LM plus BMC). FFMI was calculated by dividing
FFM by height2, and FM by subtracting FFM from total
weight. The base of the android region (Fig. 1a - shown
in blue) sits immediately above the pelvis and is in
height equal to 20 % of the distance from the pelvis to
the chin. The android and gynoid (Fig. 1a - shown in
red) regions are separated by a distance equal to 1.5
times the height of the android region, while the height
of the gynoid region is double that of the android one.
VAT was estimated within the android region [12]
(Fig. 1b number 1).
Statistical Analysis
Values are reported as means ± SD with the exception of
continuous variables, presented as median and inter-
quartile range (IQR). In order to quantify the amount of
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VAT in relation to disease severity, patients were strati-
fied for gender, BMI (cut-off of 25 kg/m2) and GOLD
stages (I + II, III, IV). Since the proportion of patients with
mild airflow limitation referred for PR is limited [18],
these patients were grouped with those with moderate air-
flow limitation. Furthermore, in order to study the impact
of VAT on lung volumes, both men and women were di-
vided in two subgroups according to VAT 50th percentile
(2183.0 g for men and 912.5 g for women).
Statistical analysis was performed using SPSS version
20.0. Comparisons across GOLD stages were performed
using ANOVA with post-hoc Tukey-Kramer tests for
multiple comparisons. Subsequently, multivariate step-
wise linear regression analysis was performed to investi-
gate a relationship between VAT and selected indices of




Patients were characterized by moderate to very severe
airflow obstruction (GOLD I/II, 44.9 %; GOLD III,
38.1 %; GOLD IV, 17.0 %). 154 (52.4 %) were men (me-
dian age 67 years, IQR 13 years; median BMI 26.9 kg/
m2, IQR 8.6 kg/m2) and 140 (47.6 %) were women (me-
dian age 61 years, IQR 13 years; median BMI 25.3 kg/
m2, IQR 8,1 kg/m2). The median number of pack/ years
smoked was 40 (IQR 24), 30.3 % of patients were current
smokers and 63.6 % of patients were former smokers.
25.5 % of patients used long-term oxygen therapy.
VAT across GOLD stages
The amount of VAT separated for men and women is
shown in Fig. 2a. In each GOLD subgroup VAT was
greater in men than in women (in all GOLD stages:
p < 0.001). Furthermore, patients with more severe
airflow obstruction had significantly lower values of
VAT, both in men (GOLD I/II: 2501.1 g ± 1141.7 g; GOLD
III: 2246.4 g ± 1488.5 g; GOLD IV: 1697.2 g ± 1350.1 g,
p =0.031) and women (GOLD I/II: 1259.7 g ± 938.0 g;
GOLD III: 1160.0 ± 929.8 g, GOLD IV: 653.0 ± 442.8 g,
p =0.015). Figure 2B shows the amount of VAT in the
three different GOLD subgroups after stratification for
BMI: as it could be expected, patients with a BMI ≥
25 kg/m2 had consistently higher values of VAT, com-
pared with those with a BMI < 25 kg/m2 (p < 0.001),
both in men and women. After stratification for gender
and BMI, differences in VAT across the three GOLD
subgroups disappeared (Fig. 2b).
Relationships of VAT with other indices of total and
central adiposity
The amount of VAT was significantly and strongly corre-
lated with BMI, waist circumference, FM, FMI, android fat
Fig. 1 a A model of total body DEXA scan. The android region is
highlighted in blue and the gynoid region is highlighted in red (refer to
text for further explanations). b Representation of visceral adipose tissue
(1) and subcutaneous adipose tissue (2) within the android region
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mass and gynoid fat mass (Fig. 3 a-f). The strength of cor-
relations was higher in male than in female patients.
Android fat mass was the most strongly correlated with
VAT (r2 = 0.919 in men; r2 = 0.857 in women), followed by
waist circumference (r2 = 0.831 in men; r2 = 0.757 in
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Fig. 2 a Visceral adipose tissue (g) in COPD male (n. 154) and female (n. 140) patients across GOLD stages, before stratification for BMI. Mean
values and standard error are reported. *: p < 0.005. b Visceral adipose tissue (g) in COPD male (n. 154) and female (n. 140) patients across GOLD
stages, after stratification for BMI. Mean values and standard error are reported. *: p < 0.005

















Fig. 3 Correlation plots of VAT with BMI (a), waist circumference (b), FM (c), FMI (d), android fat mass (e) and gynoid fat mass (f). P were <0.001
for each correlation, in both genders (o (Blue) = men; o (Green) = women)
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FMI (r2 = 0.894 in men; r2 = 0.653 in women), BMI
(r2 = 0.826 in men; r2 = 0.641 in women) and gynoid
fat (r2 = 0.746 in men; r2 = 0.467 in women).
Impact of VAT on lung volumes
Besides disease severity, patients were stratified for VAT
less and above the 50th percentile. Patients with moder-
ate to severe airflow limitation and lower VAT levels had
increased ITGV and ERV and reduced IC/TLC (Table 1)
compared to those with higher VAT levels. There was
no significant difference for FEV1 (% pred), FEV1/FVC
(%) or IVC (% pred), or for lung volumes in GOLD IV
patients.
The same trend was observed in both genders, although
it was less pronounced in female than in male patients
(data not shown). DLCO was significantly increased in pa-
tients with greater VAT in all GOLD categories (p = 0.002
in GOLD I + II; p = 0.003 in GOLD III; p = 0.015 in GOLD
IV). The same finding was true when considering male
and female patients separately.
Determinants of hyperinflation
In order to investigate whether VAT itself is a predictor
of lung hyperinflation, independently from BMI, age,
gender and FEV1 (L), stepwise regression was performed
and results are shown in Table 2. Considering IC/TLC
(%) as dependent variable (and FEV1 as the best pre-
dictor), the r2 of the regression model was 0.701. Only
FEV1 (L), BMI, age and gender are included in the
final equation and the multiple regression was signifi-
cant (p < 0.001). VAT was excluded from the model.
Similar results were obtained when choosing ITGV (L)
as dependent variable (Table 3). Only BMI, gender, FEV1
(L) and age were significant determinants, the r2 was
0.465 and the regression was significant (p < 0.001). VAT
was again excluded from the model.
Concerning diffusing capacity, stepwise regression
results showed that FEV1 (L), age, gender and BMI
were significant determinants of DLCO (L) in the way
that younger male patients and patients with higher
BMI and higher FEV1 (L), have also higher DLCO
values (Table 4). Nevertheless, VAT was again
excluded from the model. The r2 of the regression
model was high (0.532), and the regression was
significant (p < 0.001).
Discussion
The present study reported several novelties regarding
the research concerning the involvement of the adi-
pose tissue in the pathology of COPD. First, it
showed that VAT is comparable across GOLD stages
for airflow limitation if BMI is taken into account.
Second, traditional markers of total and central adi-
posity correlated very well with VAT assessed by
DEXA. Third, VAT is not an independent predictor of
static lung hyperinflation in COPD, while demograph-
ics and BMI are.
Table 1 General and clinical parameters in 294 COPD patients stratified for GOLD stages and divided in two groups, based on VAT
50th percentile (2183 g for men; 912.5 g for women)
GOLD I + II (n. 132) GOLD III (n. 112) GOLD IV (n. 50)
VAT < 50th VAT > 50th P VAT < 50th VAT > 50th P VAT < 50th VAT > 50th P
Age (years) 65.3 ± 10.9 64.9 ± 9.2 0.856 65.1 ± 10.4 65.7 ± 6.8 0.697 59.6 ± 7.5 59,1 ± 10.5 0.868
BMI (kg/m2) 24.0 ± 3.5 31.9 ± 4.4 <0.001 21.6 ± 2.9 30.5 ± 4.8 <0.001 20.7 ± 3.4 28.1 ± 4.5 <0.001
FFMI (kg/m2) 16.7 ± 2.4 18.7 ± 2.6 <0.001 15.5 ± 1.7 17.9 ± 2.5 <0.001 14.6 ± 1.4 16.9 ± 2 <0.001
FMI (kg/m2) 7.5 ± 2.0 13.2 ± 3.0 <0.001 6.4 ± 2.4 12.7 ± 3.1 <0.001 6.2 ± 2.6 11.3 ± 2.9 <0.001
Gynoid Fat (g) 3322.2 ± 1005.5 5517.6 ± 1314.4 <0.001 2770.4 ± 1031.5 5148.4 ± 1572.9 <0.001 2810.2 ± 1251.9 4737.4 ± 1397.2 <0.001
Android Fat (g) 1797.3 ± 769.0 4120.8 ± 1110.6 <0.001 1428,9 ± 736.2 3997.5 ± 1274.8 <0.001 1336.6 ± 760.1 3641.8 ± 1513.6 <0.001
FEV1 (% pred) 70.6 ± 20.6 68.9 ± 13.5 0.572 38.5 ± 5.5 39.6 ± 5.7 0.306 23.4 ± 5.0 25.2 ± 3.1 0.181
FEV1/FVC (%) 46.8 ± 11.3 49.4 ± 9.6 0.160 31.5 ± 6.7 33.4 ± 7.4 0.157 22.9 ± 4.4 26.2 ± 7.3 0.050
IVC (% pred) 115.9 ± 19.5 108.1 ± 18.7 0.021 96.3 ± 17.0 93.0 ± 15.9 0.289 79.8 ± 15.4 78.4 ± 15.0 0.750
ITGV (% pred) 132.9 ± 27.6 112.5 ± 21.9 <0.001 163.6 ± 33.1 146.0 ± 27.1 0.003 193.4 ± 35.1 174.6 ± 37.6 0.090
ERV (% pred) 132.6 ± 46.4 106.9 ± 44.9 0.002 130.6 ± 40.1 112.2 ± 35.1 0.012 106.4 ± 29.8 90.4 ± 35.9 0.103
RV (% pred) 134.0 ± 33.7 116.1 ± 26.9 0.001 178.3 ± 40.3 159.3 ± 32.6 0.008 234.5 ± 61.8 212.9 ± 48.8 0.226
IC/TLC (%) 37.9 ± 8.2 42.6 ± 7.2 0.001 26.6 ± 7.7 30.2 ± 6.5 0.008 20.3 ± 5.4 24.0 ± 5.2 0.027
DLCO (% predicted) 54.8 ± 15.9 65.5 ± 22.6 0.002 42.7 ± 12.9 50.6 ± 12.5 0.003 33.6 ± 13.1 45.1 ± 16.4 0.015
Values reported as mean ± standard deviation
BMI body mass index, FFM fat-free mass index, FMI fat mass index, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, IVC max inspiratory vital capacity,
ITGV intra-thoracic gas volume, ERV expiratory reserve volume, RV residual volume, IC inspiratory capacity, TLC total lung capacity, DLCO diffusing capacity of the
lung for carbon monoxide
Statistically significant p are indicated in bold characters
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VAT in COPD
Furutate et al. [19] investigated VAT in patients with
COPD using CT. They observed that VAT was higher in
COPD compared to controls with comparable BMI, and
that VAT tended to increase with COPD progression,
although not all differences were statistically significant.
In addition, the authors found that, in patients with se-
vere emphysema, VAT was retained despite the absence
of obesity. In the same study, BMI, waist circumference,
FFMI, FMI and SAT were shown to decrease with in-
creasing emphysematous severity. Besides the fact that
we did not relate VAT to emphysema severity, the differ-
ences in ethnicity (Furutate included a Japanese sample,
the present study population were all caucasians) be-
tween studies makes comparison difficult, but our
results indicates that VAT is comparable across GOLD
stages, after stratification for BMI.
Assessment of VAT in COPD
Several methods can be used for measuring VAT. The
most commonly used imaging technique is abdominal
CT, one of the current gold standards for quantifying
VAT [20–24]. However, because of the radiation dose
involved, the high costs and the heavily utilized clinical
equipment requirement, CT is not optimal as screening
method for VAT. MRI has also been used for VAT
measurement [25, 26]. It avoids the radiation dose in-
volved with CT measurements but still requires an ex-
pensive and time-consuming procedure as well as
heavily utilized clinical equipment. DEXA is another
suitable clinical reference method for the assessment of
body composition. It measures the differential attenu-
ation of two different energy level x-rays as they pass
through the body and subdivides soft tissue into bone,
lean and fat compartments. New software was recently
proposed to quantify VAT in the android region by
DEXA [12, 13], with several advantage relative to CT
and MRI, such as lower costs, lower x-ray exposure
and short-scanning time [27–30].
Correlates of VAT
To date, no data are available on relationships between
VAT measured by DEXA and other indices of body
composition in COPD patients. In the present study we
find a strong and significant correlation of VAT with
BMI, waist circumference, FM, FMI as well as android
and gynoid fat mass, in both genders but more strongly
in males (likely due to their higher amount of VAT com-
pared with females). As reported by Kaul et al., DEXA is
a valid tool for quantification of VAT and other adipose
tissue regions in the clinical setting [12], but more stud-
ies are needed in COPD in order to validate this method
against CT, which is one of the current gold standards
for quantifying VAT.
Hyperinflation in COPD
To the best of the authors’ knowledge, this study is the
first that carefully evaluated VAT by DEXA in relation
to static lung volumes in a large group of patients with
moderate to very severe COPD. O’Donnell et al. [31]
examined the relationship between increasing BMI and
plethysmographic lung volumes in a population with air-
flow obstruction. It was shown that lung hyperinflation
decreased exponentially with increasing BMI. However,
the potential impact of fat distribution on lung volumes
was not investigated. In the present study, patients with
greater VAT seemed to have lower ITGV, ERV, RV and
Table 3 Multivariate stepwise regression with ITGV (L) as
dependent variable





FEV1 (L) -,391 ,000
Age -,133 ,003
Independent variables: VAT, BMI, age, gender and FEV1
Adjusted R2 = 0.458. VAT was excluded from the model
*gender = 0 for women; =1 for men
Table 4 Multivariate stepwise regression with DLCO (L) as
dependent variable







Independent variables: VAT, BMI, age, gender and FEV1
Adjusted R2 = 0.525. VAT was excluded from the model
*gender = 0 for women; =1 for men
Table 2 Multivariate stepwise regression with IC/TLC (%) as
dependent variable
Model Standardized Coefficients Sig.
Beta
(Constant) ,000




Independent variables: VAT, BMI, age, gender and FEV1
Adjusted R2 = 0.697. VAT was excluded from the model
*gender = 0 for women; =1 for men
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higher IC/TLC and DLCO without a difference in FEV1,
FEV1/FVC or IVC in most GOLD stages (and most pro-
nounced in early GOLD stage). This finding appears to
confirm that the major effect of obesity is on lung vol-
umes, with no direct effect on airway obstruction [32].
The results of the multiple stepwise regression analysis
confirmed a predicted role of FEV1, BMI, gender and age
on lung hyperinflation but no independent role of VAT for
any of the lung volume parameters. This finding is some-
what surprising, since VAT is located in the abdominal
region below the respiratory compartment. Future studies
have to seek out what parameters of obesity are related to
lung hyperinflation. Probably SAT in the abdominal and
thoracic region could be worth considering.
In health, increasing BMI is known to be associated with
increasing diffusing capacity, possibly reflecting the
increased pulmonary blood volume in obesity [33, 34]. In
the current study, a relationship was confirmed between
increasing BMI and DLCO in COPD patients. Neverthe-
less, no significant predictive role of VAT on DLCO was
found.
Limitations and strengths of the study
Various limitations of the study have to be considered.
Firstly, there was no age-matched healthy control group in-
cluded in the present study. Previous studies, however,
already suggested that COPD patients have increased VAT
by CT scan compared to matched controls. Secondly, no
gold standard reference method (such as CT) was available
and future studies need to validate the DEXA device for
VAT. As mentioned in the introduction however, this
was not the aim of the present study. Beyond these lim-
itations, the major strength of this study was that it is
the first study, which used DEXA in order to measure
VAT in COPD patients. Additionally, a large population
with moderate to very severe disease and careful clin-
ical characterization was enrolled in the study.
Conclusions
In conclusion, after stratification for BMI, VAT is com-
parable across GOLD stages in moderate to very severe
COPD patients. VAT measured by DEXA is strongly
correlated to other traditional and most commonly
used body composition parameters, such as BMI, waist
circumference as well as android and gynoid fat mass.
BMI and demographics, but not VAT, were independ-
ent predictors of static lung hyperinflation and diffusing
capacity in COPD.
Clinical implications
VAT is now recognized as a risk factor for metabolic
syndrome, diabetes, and cardiovascular disease [35–41].
Furthermore, since cardiovascular disease is one of the
main comorbidities in COPD, together with type II
diabetes, skeletal muscle dysfunction and osteoporosis
[3], VAT is receiving increasing attention in clinical as-
sessment of COPD patients.
DEXA provides lots of useful information in clinical
practice. Not only is it the gold standard method for
evaluating bone mineral density and discriminate patients
with and without osteoporosis, but it is also a useful
method for the assessment of other clinically relevant
body composition parameters, among which VAT.
Abbreviation
BMI, body mass index; COPD, chronic obstructive pulmonary disease; CT,
computed tomography; DEXA, dual-energy x-ray absorptiometry; DLCO, diffusing
capacity of the lung for carbon monoxide; ERV, expiratory reserve volume; FEV1,
forced expiratory volume in 1 s; FFM, fat-free mass; FFMI, fat-free mass index; FM,
fat mass; FVC, forced vital capacity; GOLD, global initiative for chronic obstructive
lung disease; IC, inspiratory capacity; IQR, interquartile range; ITGV, intra thoracic
gas volume; IVC, inspiratory vital capacity; MRI, magnetic resonance imaging; PR,
pulmonary rehabilitation; RV, residual volume; SAT, subcutaneous adipose tissue;
TLC, total lung capacity; VAT, visceral adipose tissue.
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